Literature DB >> 22100178

Hepatotoxicity associated with lapatinib in an experimental rat model.

Umut Demirci1, Suleyman Buyukberber, Guldal Yılmaz, Mustafa Kerem, Ugur Coskun, Aytug Uner, Meltem Baykara, Hatice Pasaoglu, Hatice Pasali, Mustafa Benekli.   

Abstract

BACKGROUND: The current study is the first to evaluate the biochemical and histopathological features of hepatic toxicity of lapatinib.
METHODS: Twenty Wistar albino rats were allocated into three groups: experimental toxicity was induced with lapatinib (10mg/kg) administered for 28 days (Group 1), 42 days (Group 2) orally in a single dose by gavage. Control group received only sterile water. Rats in Group 1 and Group 2 were sacrificed after the collection of blood and tissue samples on the 28th and 42nd days, respectively.
RESULTS: Subjects in Group 1 and Group 2 had significantly higher levels of alanin aminotransferase (ALT), albumin, triglyceride and very low density lipoprotein (VLDL) when compared with the control group. None of the subjects in the two experimental groups showed normal histology. There were parenchymal acinar transformation zones, sinusoidal dilatation, hydropic degeneration of hepatocytes, vacuolisation of hepatocytes around the portal areas, and mild inflammation with dominance of mononuclear cells besides neutrophil and eosinophil leucocytes in portal areas, especially pronounced in Group 2.
CONCLUSION: This study demonstrated that lapatinib brings about deterioration of lipid profile and triggers hepatic toxicity mainly as sinusoidal injury with elevation in transaminase levels, especially ALT.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100178     DOI: 10.1016/j.ejca.2011.10.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

Review 1.  Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.

Authors:  Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain
Journal:  Biomed Res Int       Date:  2022-06-28       Impact factor: 3.246

2.  Crizotinib-induced toxicity in an experimental rat model.

Authors:  Ozge Gumusay; Guldal Esendagli-Yilmaz; Aytug Uner; Bulent Cetin; Suleyman Buyukberber; Mustafa Benekli; Mustafa N Ilhan; Ugur Coskun; Ozlem Gulbahar; Ahmet Ozet
Journal:  Wien Klin Wochenschr       Date:  2016-03-14       Impact factor: 1.704

3.  Assay of lapatinib in murine models of cigarette smoke carcinogenesis.

Authors:  Roumen Balansky; Alberto Izzotti; Francesco D'Agostini; Mariagrazia Longobardi; Rosanna T Micale; Sebastiano La Maestra; Anna Camoirano; Gancho Ganchev; Marietta Iltcheva; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2014-07-22       Impact factor: 4.944

4.  Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.

Authors:  C Villanueva; G Romieu; J Salvat; L Chaigneau; Y Merrouche; T N'guyen; A Thiery Vuillemin; M Demarchi; E Dobi; Xavier Pivot
Journal:  Target Oncol       Date:  2013-04-23       Impact factor: 4.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.